ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (
NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (
NASDAQ: IBRX) (“ImmunityBio” or the “Company”) for potential violations of the federal securities laws.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclusive.
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) for violations of the federal securities laws on behalf of investors who purchased or acquired ImmunityBio securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026NEW YORK, NY - April 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
IMMUNITYBIO Deadline to Lead in Securities Class Action Lawsuit is May 26, 2026 - Contact Kaplan FoxNEW YORK, NY - April 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
IMMUNITYBIO Deadline to Lead in Securities Class Action Lawsuit is May 26, 2026 - Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (
NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), have until Tuesday, May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the ImmunityBio class action lawsuit charges ImmunityBio and ImmunityBio’s Executive Chairman with violations of the Securities Exchange Act of 1934.
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their RightsBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options
Deadline to Lead in Securities Fraud Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deadline to Lead in Securities Fraud Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan FoxNEW YORK, NY - April 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (
NASDAQ: IBRX) on behalf of investors that purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 (the “Class Period”).
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (
NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRXNEW ORLEANS, April 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
